Entropin Inc – ‘8-K’ for 5/7/99

As of:  Friday, 5/7/99   ·   For:  5/7/99   ·   Accession #:  1017951-99-88   ·   File #:  33-23693

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         May 7, 1999 Form 8-K                                   3     12K 

Document Table of Contents

8-K
1st Page of 3
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
SECURITIES AND EXCHANGE COMMISSION          

WASHINGTON, D.C.  20549         

FORM 8-K          

CURRENT REPORT          

Pursuant to Section 13 or 15(d) of          
the Securities Exchange Act of 1934         

MAY 7, 1999           
---------------           
(Date of Report)          

ENTROPIN, INC.          
----------------------------------------------------------          
(Exact Name of Registrant as specified in its charter)          

COLORADO                33-23693            84-1090424          
----------------------------  ------------      -------------------             
(State or other jurisdiction   (Commission         (IRS Employer                
of incorporation)         File Number)      Identification No.)         

21550 OXNARD STREET, SUITE 810, WOODLAND HILLS, CA 91367        
---------------------------------------------------------------       
(Address of principal executive offices including zip code)       

(818) 340-2323        
------------------------------------------------------        
(Registrant's telephone number including area code)       

N/A       
----------------------------------------------------------------        
(Former name or former address, if changed since last report)       

8-K
2nd Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 2nd
ITEM 5.  OTHER EVENTS.                                                          
---------------------                                                           

Dewey H. Crim announced his resignation as a director from the Board  
of Directors of Entropin, Inc., effective May 1, 1999.  The vacancy created     
by his resignation shall be filled by the remaining Directors at a later date.  

On May 7, 1999, the Registrant issued the following press release:    

NEWS  RELEASE       
-------------       

FOR IMMEDIATE RELEASE                                                           

ENTROPIN INC ANNOUNCES APPOINTMENT OF NEW CHIEF EXECUTIVE       
OFFICER AND ADDITIONAL FUNDING        

Woodland Hills, CA - Entropin, Inc. today announced the appointment of          
Donald Hunter as its new Chief Executive Officer and Treasurer.  Mr. Hunter     
will also retain his position as a member of the Board of Directors.            
Through unanimous decision of the Entropin Board of Directors at its May 1,     
1999 meeting, Mr. Hunter will replace Dewey H. Crim who resigned as CEO and     
a director.                                                                     

Mr. Hunter has over thirty-five years of senior executive experience, most      
recently serving as Senior Vice President of Entergy Corporation as well as     
COO of Louisiana Power and Light.  He has extensive business experience         
including mergers and acquisitions. Don has a B.S. degree in chemical           
engineering from Purdue University and a M.S. in nuclear engineering from       
Iowa State University.                                                          

Entropin's Chairman of the Board Directors, Higgins Bailey, commented on        
the appointment of Mr. Hunter, stating "The Board is extremely pleased in       
the appointment of Don as CEO.  We have been fortunate to have Don serve as     
a member of the Board and the Executive Management Team.  We will now be        
able to more fully utilize his extensive background and skills as Entropin      
approaches its next critical stages of development in both the                  
commercialization of its first product, Esterom(R), and establishing            
strategic relationships within the pharmaceutical industry."                    

The Company also announced the completion of a $1.2mm bridge financing, the     
proceeds of which will be used for prerequisite activities in preparation       
for the commencement of the Phase III Clinical Trial which has been allowed     
to begin by the FDA and is scheduled for early summer.  The Company is          
currently undertaking an additional $8mm equity financing to fund the Phase     
III Trial and the New Drug Application with the FDA.                            

Entropin is a pharmaceutical development company whose first product,           
Esterom(R) is a unique topical preparation for the treatment of impaired        
range of motion.  A successful Phase II Clinical trial was completed            
showing both safety and efficacy in the treatment of acute lower back           
sprain, and acute painful shoulder.  Results of that Phase II Trial were        
accepted by the FDA, which has allowed                                          

-2-       

8-K
Last Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 3rd
the Company to begin a Phase III Clinical Trial.  Seven U.S. patents have       
been allowed on the Esterom(R) technology, with over 16 years of protection     
remaining, and applications in 29 foreign countries have been submitted.        

SIGNATURES        
----------        

Pursuant to the requirements of the Securities Exchange Act of 1934,  
the Registrant has duly caused this Report to be signed on its behalf by        
the undersigned, thereunto duly authorized.                                     

Date: May 7, 1999                  ENTROPIN, INC.                               

               By /s/ WELLINGTON A. EWEN
                        ------------------------------
            Wellington A. Ewen
                 Chief Financial Officer

-3-       

Dates Referenced Herein

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed on / For Period End:		5/7/99		1		3			None on these Dates
		5/1/99		2
									List all Filings